U.S. markets open in 1 hour 21 minutes
  • S&P Futures

    3,633.75
    +6.50 (+0.18%)
     
  • Dow Futures

    29,890.00
    +62.00 (+0.21%)
     
  • Nasdaq Futures

    12,194.75
    +42.50 (+0.35%)
     
  • Russell 2000 Futures

    1,843.10
    -1.50 (-0.08%)
     
  • Crude Oil

    45.35
    -0.36 (-0.79%)
     
  • Gold

    1,810.70
    -0.50 (-0.03%)
     
  • Silver

    23.31
    -0.14 (-0.60%)
     
  • EUR/USD

    1.1926
    +0.0013 (+0.11%)
     
  • 10-Yr Bond

    0.8780
    -0.0040 (-0.45%)
     
  • Vix

    21.47
    -0.17 (-0.79%)
     
  • GBP/USD

    1.3324
    -0.0032 (-0.24%)
     
  • USD/JPY

    104.1200
    -0.1300 (-0.12%)
     
  • BTC-USD

    16,805.99
    -360.66 (-2.10%)
     
  • CMC Crypto 200

    328.62
    -41.89 (-11.31%)
     
  • FTSE 100

    6,345.32
    -17.61 (-0.28%)
     
  • Nikkei 225

    26,644.71
    +107.40 (+0.40%)
     

What Type Of Shareholders Own The Most Number of Strongbridge Biopharma plc (NASDAQ:SBBP) Shares?

Simply Wall St
·5 min read

If you want to know who really controls Strongbridge Biopharma plc (NASDAQ:SBBP), then you'll have to look at the makeup of its share registry. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. Companies that used to be publicly owned tend to have lower insider ownership.

Strongbridge Biopharma is a smaller company with a market capitalization of US$194m, so it may still be flying under the radar of many institutional investors. Our analysis of the ownership of the company, below, shows that institutions are noticeable on the share registry. Let's take a closer look to see what the different types of shareholders can tell us about Strongbridge Biopharma.

See our latest analysis for Strongbridge Biopharma

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Strongbridge Biopharma?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

As you can see, institutional investors have a fair amount of stake in Strongbridge Biopharma. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Strongbridge Biopharma's historic earnings and revenue below, but keep in mind there's always more to the story.

earnings-and-revenue-growth
earnings-and-revenue-growth

Our data indicates that hedge funds own 18% of Strongbridge Biopharma. That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders. The company's largest shareholder is Caxton Associates LP, with ownership of 12%. Novo Nordisk A/S is the second largest shareholder owning 9.6% of common stock, and Longitude Capital Management Co., LLC holds about 8.3% of the company stock.

We also observed that the top 7 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.

Insider Ownership Of Strongbridge Biopharma

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

Our information suggests that Strongbridge Biopharma plc insiders own under 1% of the company. It appears that the board holds about US$1.2m worth of stock. This compares to a market capitalization of US$194m. I generally like to see a board more invested. However it might be worth checking if those insiders have been buying.

General Public Ownership

With a 21% ownership, the general public have some degree of sway over Strongbridge Biopharma. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Private Equity Ownership

With a stake of 22%, private equity firms could influence the Strongbridge Biopharma board. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

Public Company Ownership

Public companies currently own 9.6% of Strongbridge Biopharma stock. It's hard to say for sure but this suggests they have entwined business interests. This might be a strategic stake, so it's worth watching this space for changes in ownership.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand Strongbridge Biopharma better, we need to consider many other factors. To that end, you should be aware of the 1 warning sign we've spotted with Strongbridge Biopharma .

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.